MA35194B1 - Derives de benzamide substitues - Google Patents
Derives de benzamide substituesInfo
- Publication number
- MA35194B1 MA35194B1 MA36585A MA36585A MA35194B1 MA 35194 B1 MA35194 B1 MA 35194B1 MA 36585 A MA36585 A MA 36585A MA 36585 A MA36585 A MA 36585A MA 35194 B1 MA35194 B1 MA 35194B1
- Authority
- MA
- Morocco
- Prior art keywords
- disorders
- halogen
- lower alkoxy
- substituted
- diabetes
- Prior art date
Links
- 150000003936 benzamides Chemical class 0.000 title 1
- 229910052736 halogen Inorganic materials 0.000 abstract 4
- 125000005843 halogen group Chemical group 0.000 abstract 4
- 125000003545 alkoxy group Chemical group 0.000 abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 3
- 208000035475 disorder Diseases 0.000 abstract 3
- 208000030814 Eating disease Diseases 0.000 abstract 2
- 208000019454 Feeding and Eating disease Diseases 0.000 abstract 2
- 125000000217 alkyl group Chemical group 0.000 abstract 2
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 2
- 206010012601 diabetes mellitus Diseases 0.000 abstract 2
- 235000014632 disordered eating Nutrition 0.000 abstract 2
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 208000019901 Anxiety disease Diseases 0.000 abstract 1
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 abstract 1
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 abstract 1
- 208000020925 Bipolar disease Diseases 0.000 abstract 1
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 1
- 208000017164 Chronobiology disease Diseases 0.000 abstract 1
- 208000032928 Dyslipidaemia Diseases 0.000 abstract 1
- 206010020772 Hypertension Diseases 0.000 abstract 1
- 208000017170 Lipid metabolism disease Diseases 0.000 abstract 1
- 208000019695 Migraine disease Diseases 0.000 abstract 1
- 208000012902 Nervous system disease Diseases 0.000 abstract 1
- 208000025966 Neurological disease Diseases 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- 208000018737 Parkinson disease Diseases 0.000 abstract 1
- 208000028017 Psychotic disease Diseases 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 230000009045 body homeostasis Effects 0.000 abstract 1
- 230000027288 circadian rhythm Effects 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000007812 deficiency Effects 0.000 abstract 1
- 206010013663 drug dependence Diseases 0.000 abstract 1
- 230000008482 dysregulation Effects 0.000 abstract 1
- 206010015037 epilepsy Diseases 0.000 abstract 1
- 150000002367 halogens Chemical group 0.000 abstract 1
- 150000002431 hydrogen Chemical group 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- 208000013403 hyperactivity Diseases 0.000 abstract 1
- 208000030159 metabolic disease Diseases 0.000 abstract 1
- 206010027599 migraine Diseases 0.000 abstract 1
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 201000000980 schizophrenia Diseases 0.000 abstract 1
- 208000019116 sleep disease Diseases 0.000 abstract 1
- 208000011117 substance-related disease Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
- C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Psychiatry (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Emergency Medicine (AREA)
- Anesthesiology (AREA)
- Endocrinology (AREA)
- Addiction (AREA)
- Child & Adolescent Psychology (AREA)
- Nutrition Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Cette invention concerne des composés de formule (i), ou un sel d'addition d'acide pharmaceutiquement acceptable de ceux-ci, qui peuvent être utilisés pour traiter la dépression, les troubles de l'anxiété, le trouble bipolaire, les troubles déficitaires de l'attention avec hyperactivité (tdah), les troubles liés au stress, les troubles psychotiques, la schizophrénie, les maladies neurologiques, la maladie de parkinson, les troubles neurodégénératifs, la maladie d'alzheimer, l'épilepsie, la migraine, l'hypertension, la toxicomanie, les troubles métaboliques, les troubles du comportement alimentaire, le diabète, les complications du diabète, l'obésité, la dyslipidémie, les troubles de la consommation et de l'assimilation énergétique, les troubles et le dérèglement de l'homéostasie de la température corporelle, les troubles du sommeil et du rythme circadien, et les troubles cardiovasculaires. Dans la formule (i), r1 est un atome d'hydrogène, un halogène, un groupe cyano, alkyle inférieur, alkyle inférieur substitué par un atome d'halogène, alcoxy inférieur, alcoxy inférieur substitué par un atome d'halogène ou c(o)nh2, ou est un phényle éventuellement substitué par un halogène, un cyano ou un alcoxy inférieur substitué par un atome d'halogène, ou est un 2,2-difluorobenzo[d][l,3]
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11169441 | 2011-06-10 | ||
| PCT/EP2012/060637 WO2012168265A1 (fr) | 2011-06-10 | 2012-06-06 | Dérivés de benzamide substitués |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA35194B1 true MA35194B1 (fr) | 2014-06-02 |
Family
ID=46298391
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA36585A MA35194B1 (fr) | 2011-06-10 | 2013-12-18 | Derives de benzamide substitues |
Country Status (32)
| Country | Link |
|---|---|
| US (1) | US9029370B2 (fr) |
| EP (1) | EP2718271B1 (fr) |
| JP (1) | JP5788087B2 (fr) |
| KR (1) | KR101574906B1 (fr) |
| CN (1) | CN103596937B (fr) |
| AR (1) | AR086880A1 (fr) |
| AU (1) | AU2012266462B2 (fr) |
| BR (1) | BR112013030698B1 (fr) |
| CA (1) | CA2834675C (fr) |
| CL (1) | CL2013003485A1 (fr) |
| CO (1) | CO6811866A2 (fr) |
| CY (1) | CY1116769T1 (fr) |
| DK (1) | DK2718271T3 (fr) |
| EA (1) | EA022376B1 (fr) |
| EC (1) | ECSP13013073A (fr) |
| ES (1) | ES2546529T3 (fr) |
| HR (1) | HRP20151201T1 (fr) |
| IL (1) | IL229335A (fr) |
| MA (1) | MA35194B1 (fr) |
| MX (1) | MX354410B (fr) |
| MY (1) | MY162461A (fr) |
| PE (1) | PE20140968A1 (fr) |
| PH (1) | PH12013502263A1 (fr) |
| PL (1) | PL2718271T3 (fr) |
| PT (1) | PT2718271E (fr) |
| RS (1) | RS54415B1 (fr) |
| SG (1) | SG194840A1 (fr) |
| SI (1) | SI2718271T1 (fr) |
| TW (1) | TWI445701B (fr) |
| UA (1) | UA110388C2 (fr) |
| WO (1) | WO2012168265A1 (fr) |
| ZA (1) | ZA201308401B (fr) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9073911B2 (en) * | 2011-06-09 | 2015-07-07 | Hoffmann-La Roche Inc. | Pyrazole derivatives |
| KR101631003B1 (ko) | 2012-01-12 | 2016-06-15 | 에프. 호프만-라 로슈 아게 | 미량 아민 결합 수용체(taar)로서 헤테로환형 유도체 |
| EA026062B1 (ru) * | 2012-09-14 | 2017-02-28 | Ф. Хоффманн-Ля Рош Аг | Производные пиразолкарбоксамида в качестве модуляторов рецепторов следовых аминов (taar) для применения при лечении различных расстройств, таких как депрессия, диабет и болезнь паркинсона |
| HK1206714A1 (en) * | 2012-09-17 | 2016-01-15 | 霍夫曼-拉罗奇有限公司 | Triazole carboxamide derivatives |
| WO2014072257A1 (fr) * | 2012-11-07 | 2014-05-15 | F. Hoffmann-La Roche Ag | Dérivés de pyrazine |
| WO2015165085A1 (fr) * | 2014-04-30 | 2015-11-05 | F.Hoffmann-La Roche Ag | Dérivés de morpholine-pyridine |
| KR101880841B1 (ko) * | 2014-05-28 | 2018-07-20 | 에프. 호프만-라 로슈 아게 | 미량 아민 결합 수용체 1(taar1) 조절제로서 5-옥사-2-아자바이사이클로[2.2.2]옥탄-4-일 및 5-옥사-2-아자바이사이클로[2.2.1]헵탄-4-일 유도체 |
| CN104478798B (zh) * | 2014-12-18 | 2017-01-18 | 武汉华纳联合药业有限公司 | N‑氨基烷基磺酰基‑3‑吡啶甲酰胺衍生物及其在制备治疗心脑血管病药物中的应用 |
| MY195528A (en) * | 2016-03-17 | 2023-01-30 | Hoffmann La Roche | 5-Ethyl-4-Methyl-Pyrazole-3-Carboxamide Derivative Having Activity as Agonist of Taar |
| CN114144412A (zh) * | 2019-07-11 | 2022-03-04 | 豪夫迈·罗氏有限公司 | 用于制备经取代的吡唑衍生物的方法 |
| MX2022010693A (es) * | 2020-02-28 | 2022-09-26 | Univ Texas | Compuestos, composiciones y metodos para inhibidores de la proteina quinasa que interactua con el receptor i para el tratamiento de enfermedades. |
| WO2024118488A1 (fr) * | 2022-11-28 | 2024-06-06 | Sumitomo Pharma America, Inc. | Composés de 2-phénylmorpholine et de 2-phényl(thio)morpholine et utilisations associées |
| WO2025165773A1 (fr) * | 2024-02-01 | 2025-08-07 | Board Of Regents, The University Of Texas System | Inhibiteurs de la protéine kinase 1 interagissant avec des récepteurs pour le traitement d'une maladie |
| WO2025165774A1 (fr) * | 2024-02-01 | 2025-08-07 | Board Of Regents, The University Of Texas System | Inhibiteurs de la protéine kinase 1 interagissant avec des récepteurs pour le traitement d'une maladie |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9425211D0 (en) | 1994-12-14 | 1995-02-15 | Ucb Sa | Substituted 1H-imidazoles |
| GB9520150D0 (en) | 1995-10-03 | 1995-12-06 | Orion Yhtymae Oy | New imidazole derivatives |
| BR9813381A (pt) | 1997-12-04 | 2000-10-03 | Allergan Sales Inc | "derivados de imidazol substituìdo possuindo atividade semelhante a agonista em receptores adrenérgicos alfa 2b ou 2b/2c" |
| US6841684B2 (en) | 1997-12-04 | 2005-01-11 | Allergan, Inc. | Imidiazoles having reduced side effects |
| AR050865A1 (es) * | 2004-09-09 | 2006-11-29 | Sanofi Aventis | Derivados de 2- morfolino-4-pirimidona |
| WO2008026046A1 (fr) | 2006-08-30 | 2008-03-06 | Pfizer Products Inc. | Antagonistes à base de morpholine de la dopamine d3 |
| CL2007003874A1 (es) * | 2007-01-03 | 2008-05-16 | Boehringer Ingelheim Int | Compuestos derivados de benzamida; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar enfermedades cardiovasculares, hipertension, aterosclerosis, reestenosis, ictus, insuficiencia cardiaca, lesion isquemica, hipertensio |
| BRPI0806932A2 (pt) * | 2007-02-02 | 2014-05-06 | Novartis Ag | Antagonista do receptor s1p1 de cromeno |
| MX2009008465A (es) | 2007-02-15 | 2009-08-20 | Hoffmann La Roche | Nuevas 2-aminooxazolinas como ligandos de taar1. |
| AU2008281877A1 (en) | 2007-08-02 | 2009-02-05 | F. Hoffmann-La Roche Ag | The use of benzamide derivatives for the treatment of CNS disorders |
| AR077969A1 (es) | 2009-08-31 | 2011-10-05 | Abbott Healthcare Products Bv | Derivados de (tio)morfolina comomoduladores de s1p |
| CA2771822C (fr) | 2009-09-04 | 2020-08-11 | Daniel A. Erlanson | Inhibiteurs de tyrosine kinase de bruton |
| US8354441B2 (en) | 2009-11-11 | 2013-01-15 | Hoffmann-La Roche Inc. | Oxazoline derivatives |
| US9452980B2 (en) * | 2009-12-22 | 2016-09-27 | Hoffmann-La Roche Inc. | Substituted benzamides |
| US9132136B2 (en) | 2010-08-02 | 2015-09-15 | Hoffmann-La Roche Inc. | Pharmaceutical combination |
| US9073911B2 (en) * | 2011-06-09 | 2015-07-07 | Hoffmann-La Roche Inc. | Pyrazole derivatives |
-
2012
- 2012-06-01 US US13/485,993 patent/US9029370B2/en active Active
- 2012-06-06 PH PH1/2013/502263A patent/PH12013502263A1/en unknown
- 2012-06-06 BR BR112013030698-0A patent/BR112013030698B1/pt not_active IP Right Cessation
- 2012-06-06 ES ES12727633.5T patent/ES2546529T3/es active Active
- 2012-06-06 JP JP2014514044A patent/JP5788087B2/ja not_active Expired - Fee Related
- 2012-06-06 EP EP12727633.5A patent/EP2718271B1/fr active Active
- 2012-06-06 MX MX2013014371A patent/MX354410B/es active IP Right Grant
- 2012-06-06 WO PCT/EP2012/060637 patent/WO2012168265A1/fr not_active Ceased
- 2012-06-06 PL PL12727633T patent/PL2718271T3/pl unknown
- 2012-06-06 KR KR1020147000701A patent/KR101574906B1/ko not_active Expired - Fee Related
- 2012-06-06 SI SI201230320T patent/SI2718271T1/sl unknown
- 2012-06-06 MY MYPI2013003963A patent/MY162461A/en unknown
- 2012-06-06 EA EA201391815A patent/EA022376B1/ru not_active IP Right Cessation
- 2012-06-06 CA CA2834675A patent/CA2834675C/fr active Active
- 2012-06-06 HR HRP20151201TT patent/HRP20151201T1/hr unknown
- 2012-06-06 PE PE2013002778A patent/PE20140968A1/es active IP Right Grant
- 2012-06-06 AU AU2012266462A patent/AU2012266462B2/en not_active Ceased
- 2012-06-06 RS RS20150747A patent/RS54415B1/sr unknown
- 2012-06-06 PT PT127276335T patent/PT2718271E/pt unknown
- 2012-06-06 UA UAA201400121A patent/UA110388C2/ru unknown
- 2012-06-06 CN CN201280028534.4A patent/CN103596937B/zh not_active Expired - Fee Related
- 2012-06-06 DK DK12727633.5T patent/DK2718271T3/en active
- 2012-06-06 SG SG2013082656A patent/SG194840A1/en unknown
- 2012-06-07 TW TW101120551A patent/TWI445701B/zh not_active IP Right Cessation
- 2012-06-08 AR ARP120102045A patent/AR086880A1/es unknown
-
2013
- 2013-11-07 IL IL229335A patent/IL229335A/en active IP Right Grant
- 2013-11-07 ZA ZA2013/08401A patent/ZA201308401B/en unknown
- 2013-11-29 CO CO13281375A patent/CO6811866A2/es active IP Right Grant
- 2013-12-05 CL CL2013003485A patent/CL2013003485A1/es unknown
- 2013-12-10 EC ECSP13013073 patent/ECSP13013073A/es unknown
- 2013-12-18 MA MA36585A patent/MA35194B1/fr unknown
-
2015
- 2015-10-06 CY CY20151100894T patent/CY1116769T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA35192B1 (fr) | Derives de pyrazole | |
| MA32486B1 (fr) | Derives de 4,5- dihydrooxazol-2-yle | |
| MA35062B1 (fr) | Dérivés d'amines hétérocycliques | |
| MA31165B1 (fr) | Nouvelles 2-aminooxazolines servant de ligands du taar1 pour des troubles du snc | |
| TW200738645A (en) | Use of 4-imidazole derivatives for CNS disorders | |
| MX2012007409A (es) | Derivados de benzamida sustituidos. | |
| MX354815B (es) | Derivados heterociclicos como receptores asociados con las aminas traza (taars). | |
| TW200738690A (en) | Use of 2-imidazoles for the treatment of CNS disorders | |
| MX2015001108A (es) | Derivados de triazol carboxamida. | |
| MX2009003887A (es) | Aminometil-2-imidazoles con afinidad con los receptores asociados a trazas de amina. | |
| MX2012005363A (es) | Derivados de oxazolina para el tratamiento de trastornos del sistema nervioso central (snc). | |
| MX2009005920A (es) | Nuevos 2-imidazoles como ligandos para receptores asociados con trazas de amina. | |
| MA37944A1 (fr) | Dérivés de pyrazole-carboxamide en tant que modulateurs de taar pour utilisation dans le traitement de plusieurs troubles, tels que la dépression, le diabète et la maladie de parkinson | |
| MX2016016488A (es) | Derivados de azetidina sustituidos como ligandos de receptores asociados a aminas en trazas (taar). | |
| MX2009006215A (es) | 4-imidazolinas como ligandos de aminas trazas. | |
| MX377195B (es) | Derivados de morfolina-piridina. | |
| MX2009013745A (es) | 4-imidazolinas y su uso como antidepresivos. | |
| WO2007090720A3 (fr) | Utilisation de 2-imidazoles pour le traitement de troubles du système nerveux central | |
| MX349738B (es) | Derivados de dihidrooxazol-2-amina. | |
| MX2009004617A (es) | 2-imidazoles sustituidos como moduladores de los receptores asociados con trazas de amina. | |
| MX2015005721A (es) | Derivados de pirazina. | |
| MX2009005047A (es) | 4-imidazoles sustituidos. | |
| RU2010104632A (ru) | 2-азетидинметанамины и 2-пирролидинметанамины в качестве лигандов taar |